A randomized controlled trial investigating the neurocognitive effects of Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly participants with age-associated memory impairment: The Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a randomized controlled trial by Scholey, Andrew B et al.
University of Wollongong 
Research Online 
Faculty of Social Sciences - Papers Faculty of Arts, Social Sciences & Humanities 
1-1-2013 
A randomized controlled trial investigating the neurocognitive effects of 
Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly 
participants with age-associated memory impairment: The Phospholipid 
Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a 
randomized controlled trial 
Andrew B. Scholey 
Swinburne University of Technology, andrew@scholeylab.com 
David A. Camfield 
Swinburne University of Technology, dcamfield@swin.edu.au 
Matthew E. Hughes 
Swinburne University of Technology, matthewhughes@swin.edu.au 
Will Woods 
Swinburne University of Technology 
Con K. Stough 
Swinburne University of Technology, cstough@swin.edu.au 
See next page for additional authors 
Follow this and additional works at: https://ro.uow.edu.au/sspapers 
 Part of the Education Commons, and the Social and Behavioral Sciences Commons 
Recommended Citation 
Scholey, Andrew B.; Camfield, David A.; Hughes, Matthew E.; Woods, Will; Stough, Con K.; White, David J.; 
Gondalia, Shakuntla V.; and Frederiksen, Pernille D., "A randomized controlled trial investigating the 
neurocognitive effects of Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly 
participants with age-associated memory impairment: The Phospholipid Intervention for Cognitive Ageing 
Reversal (PLICAR): study protocol for a randomized controlled trial" (2013). Faculty of Social Sciences - 
Papers. 505. 
https://ro.uow.edu.au/sspapers/505 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
A randomized controlled trial investigating the neurocognitive effects of 
Lacprodan® PL-20, a phospholipid-rich milk protein concentrate, in elderly 
participants with age-associated memory impairment: The Phospholipid 
Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a 
randomized controlled trial 
Abstract 
Background: Age-related cognitive decline (ARCD) is of major societal concern in an ageing population, 
with the development of dietary supplements providing a promising avenue for amelioration of 
associated deficits. Despite initial interest in the use of phospholipids (PLs) for ARCD, in recent years 
there has been a hiatus in such research. Because of safety concerns regarding PLs derived from bovine 
cortex, and the equivocal efficacy of soybean-derived PLs, there is an important need for the development 
of new PL alternatives. Phospholipids derived from milk proteins represent one potential candidate 
treatment. 
Methods: In order to reduce the effects of age-associated memory impairment (AAMI) the Phospholipid 
Intervention for Cognitive Ageing Reversal (PLICAR) was developed to test the efficacy of a milk protein 
concentrate rich in natural, non-synthetic milk phospholipids (Lacprodan® PL-20). PLICAR is a 
randomized, double-blind, placebo-controlled parallel-groups study where 150 (N = 50/group) AAMI 
participants aged > 55 years will be randomized to receive a daily supplement of Lacprodan® PL-20 or 
one of two placebos (phospholipid-free milk protein concentrate or inert rice starch) over a 6-month 
(180-day) period. Participants will undergo testing at baseline, 90 days and 180 days. The primary 
outcome is a composite memory score from the Rey Auditory Verbal Learning Test. Secondary outcomes 
include cognitive (verbal learning, working memory, prospective and retrospective memory, processing 
speed and attention), mood (depression, anxiety, stress and visual analogue scales), cardiovascular 
(blood pressure, blood velocity and pulse wave pressure), gastrointestinal microbiota and biochemical 
measures (oxidative stress, inflammation, B vitamins and Homocysteine, glucoregulation and serum 
choline). Allelic differences in the Apolipoprotein E and (APOE) and Methylenetetrahydrofolate reductase 
(MTHFR) gene will be included for subgroup analysis. A subset (N = 60; 20/group)) will undergo 
neuroimaging using functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG) 
in order to further explore in vivo central mechanisms of action of Lacprodan® PL-20. This study will 
enable evaluation of the efficacy of milk-derived phospholipids for AAMI, and their mechanisms of action. 
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A randomized controlled trial investigating the
neurocognitive effects of Lacprodan® PL-20, a
phospholipid-rich milk protein concentrate, in
elderly participants with age-associated memory
impairment: the Phospholipid Intervention for
Cognitive Ageing Reversal (PLICAR): study
protocol for a randomized controlled trial
Andrew B Scholey1*, David A Camfield1, Matthew E Hughes2, Will Woods2, Con K K Stough1, David J White1,
Shakuntla V Gondalia1 and Pernille D Frederiksen3
Abstract
Background: Age-related cognitive decline (ARCD) is of major societal concern in an ageing population, with the
development of dietary supplements providing a promising avenue for amelioration of associated deficits. Despite
initial interest in the use of phospholipids (PLs) for ARCD, in recent years there has been a hiatus in such research.
Because of safety concerns regarding PLs derived from bovine cortex, and the equivocal efficacy of soybean-derived
PLs, there is an important need for the development of new PL alternatives. Phospholipids derived from milk proteins
represent one potential candidate treatment.
Methods: In order to reduce the effects of age-associated memory impairment (AAMI) the Phospholipid Intervention
for Cognitive Ageing Reversal (PLICAR) was developed to test the efficacy of a milk protein concentrate rich in natural,
non-synthetic milk phospholipids (Lacprodan® PL-20). PLICAR is a randomized, double-blind, placebo-controlled
parallel-groups study where 150 (N = 50/group) AAMI participants aged > 55 years will be randomized to receive a daily
supplement of Lacprodan® PL-20 or one of two placebos (phospholipid-free milk protein concentrate or inert rice
starch) over a 6-month (180-day) period. Participants will undergo testing at baseline, 90 days and 180 days. The primary
outcome is a composite memory score from the Rey Auditory Verbal Learning Test. Secondary outcomes include
cognitive (verbal learning, working memory, prospective and retrospective memory, processing speed and attention),
mood (depression, anxiety, stress and visual analogue scales), cardiovascular (blood pressure, blood velocity and pulse
wave pressure), gastrointestinal microbiota and biochemical measures (oxidative stress, inflammation, B vitamins and
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Homocysteine, glucoregulation and serum choline). Allelic differences in the Apolipoprotein E and (APOE) and
Methylenetetrahydrofolate reductase (MTHFR) gene will be included for subgroup analysis. A subset (N = 60; 20/group))
will undergo neuroimaging using functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG)
in order to further explore in vivo central mechanisms of action of Lacprodan® PL-20. This study will enable evaluation
of the efficacy of milk-derived phospholipids for AAMI, and their mechanisms of action.
Trial Registration: The trial is jointly funded by Arla Foods and Swinburne University of Technology, currently
recruiting and is registered on the Australian New Zealand Clinical Trials Registry as ACTRN12613000347763.
Background
Cognitive deficits including learning and memory impair-
ment are one of the most prominent and debilitating con-
sequences of normal and pathological ageing in humans.
A consistent finding in research on ageing and cognition
is that performance across various tests of memory is
lower with increased age. Meta-analyses of cross-sectional
and longitudinal datasets have demonstrated approximately
40 to 60% decline in cognitive speed at age 80 compared to
age 20 years in non-demented adults [1]. These cognitive
deficits are of considerable concern to elderly individuals,
with up to 50% of adults aged 64 years or older reporting
difficulties with their memory [2]. There is an increasing
awareness of the possibility that dietary modification can
alter the course of age-related cognitive decline.
Frequent dairy food intake is associated with better
cognitive function, although the exact underlying mecha-
nisms are yet to be determined. The positive correlation
between increased dairy intake and cognitive function
seems partly to be a result of counteracting metabolic
syndrome, by reducing cardiovascular (CV) risk factors
such as type 2 diabetes, hypertension, obesity and hyper-
lipedimia [3-5]. In a recent paper by Crichton et al. [6],
the authors support this link and in addition argue that
apart from counteracting the CV risk factors, dairy
consumption provides additional benefits in relation to
cognitive function (for example, after adjusting for CV
disease, lifestyle and dietary factors). Recent advances in
dairy manufacturing, which enable the enrichment of
phospholipid components in milk also offer a promising
new avenue for the treatment of age-related cognitive
decline.
Phospholipids and the amelioration of cognitive decline
Bovine milk contains a vast range of phospholipids
and complex lipids, with important biological functions.
Phospholipids are substances with both a hydrophilic
(water-liking) head and hydrophobic (water-repellent) tail
segment which are major building blocks for cellular
membranes, including neuronal cells, where they arrange
themselves into lipid bilayers [7]. Relevant phospholipids
in relation to cognitive performance include phosphati-
dylserine (PS) and phosphatidylcholine (PC) as well as
the related substances sphingomyelin and the sialic-
acid-containing gangliosides. Pharmacokinetic studies
of PS have revealed good bioavailability when consumed
orally. Following ingestion, the headgroup is absorbed
intact through the intestinal wall into the bloodstream,
while the fatty-acid tail segments at position 2 are often
removed and later re-added. After crossing the blood–
brain barrier the fatty acid at position 2 is typically oc-
cupied by either oleic (C18:1) or docosahexaenoic acid
(DHA, C22:6) in the brain [8,9].
Phosphatidylserine (PS)
PS is a naturally occurring membrane phospholipid
that is found in high concentrations in brain tissue,
where it comprises 10 to 20% of the total phospho-
lipid pool [10]. PS plays an important role in a host of
cellular functions including mitochondrial membrane
integrity, presynaptic neurotransmitter release, post-
synaptic receptor activity and activation of protein
kinase C in memory formation [7,11]. PS enhances the
activities of membrane-bound enzymes involved in signal
transduction [12] and plays a key role in the biosyn-
thesis and release of several neurotransmitters, including
acetylcholine [13,14], norepinephrine [15], serotonin and
dopamine [16]. PS has also been found to elevate glucose
metabolism [17].
In relation to the cholinergic system, PS has been
found to restore age-related decreases in choline-
acetyltransferase-positive neurons [18] as well as dens-
ities of muscarinic and N-methyl-D-aspartate (NMDA)
receptors [19,20]. Increases in nerve growth factor (NGF)-
receptor density have been reported in aged animals
following PS supplementation, as well as increases in
neuronal numbers and size [21]. Other beneficial effects of
PS supplementation include protection from cell death
[22] due to increased membrane fluidity [23] as well as
anti-inflammatory and antioxidant effects [24]. Behavioural
animal experiments using PS have provided evidence of
improvements in spatial memory [25], retention of passive
avoidance [15], exploration and memory retrieval [26] as
well as improvement of avoidance performance [27]. Pre-
vention of scopolamine-induced learning deficits have also
been reported [28-31], together with an attenuation of
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memory deficits associated with reserpine-induced cat-
echolamine depletion [32].
PS is the most studied of the phospholipids in regards
to human clinical trials of dementia and cognitive de-
cline. Five double-blind randomized trials have been
conducted using PS in Alzheimer’s disease (AD) [33-37].
Clinical global impressions of change and activities of
daily living were found to be improved with daily doses
of 200 to 300 mg up to six months. In milder cases of
AD, significant improvements to concentration, learning
and memory for names, locations and recent events
were also observed [7,11]. In the largest of these studies
involving 494 elderly patients with moderate to severe
cognitive decline, Cenacchi et al. [37] reported improve-
ments to memory and learning following 300 mg PS/day
for 6 months.
In elderly populations with mild cognitive impairment
and age-associated memory impairment (AAMI), PS has
also been found to be effective in ameliorating cognitive
declines. Crook et al. [38] administered 300 mg/day PS
to 149 elderly patients (aged 50 to 75 years) with age-
associated memory impairment for 12 weeks, and ob-
served significant improvements in performance tests of
learning and recall abilities such as name-face matching.
In a multi-centre trial by Villardita et al. [39], 300 mg/day
PS versus placebo was administered to 170 elderly patients
for 90 days. Significant improvements in attention, con-
centration and short-term memory were found in those
receiving PS. These earlier trials were conducted using
PS derived from bovine cortex, but more recently trials
have also been conducted using soybean (SB)-derived PS
due to concerns over bovine spongiform encephalop-
athy. The results in relation to SB-PS have been more
mixed, with Jorissen et al. [40] reporting no significant
effects on learning and memory, whereas more recently
Vakhaporva et al. [41] and Kato-Kataoka et al. [42] re-
ported significant improvements to verbal learning follow-
ing ≥3 months supplementation. An intriguing study by
Hellhammer et al. [43] using the same milk-derived phos-
pholipids as the current study (PL-20) also reported
improvements to working memory function following
3 weeks supplementation in healthy adults aged 30 to
55 years.
Phosphatidylcholine (PC)
Choline is an essential nutrient critically needed for syn-
thesis of the neurotransmitter acetylcholine; important
in brain functions, such as memory and mood, but also
important in skeletal-muscle control, heart rate and
breathing. Numerous animal studies demonstrate that
choline is necessary for normal development of the
memory function and sub-optimal dietary intake of cho-
line by the pregnant mother and later by the infant and
child directly affects brain development and results
in permanent changes in brain function (Zeisel et al.
1991). Choline or its metabolites, are also needed for
the structural integrity and signaling functions of cell
membranes; it is the major source of methyl-groups in
the diet (one of choline’s metabolites, betaine, partici-
pates in the methylation of homocysteine (HCy) to form
methionine), and it directly affects cholinergic neuro-
transmission, transmembrane signaling and lipid trans-
port/metabolism [44,45]. Nagata et al. [46] documented
recently that dietary supplements of PhosChol compounds
(1,2-dilinoleoyl-sn-glycero-3-phosphocholine; DL-PC and
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; PO-PC) )
enhanced the memory and learning ability in the elderly
in the Mini Mental State Examination (MMSE). In an-
other placebo-controlled clinical trial, Ladd et al. [47]
found that the supplementation of SB-PC in normal col-
lege students lead to an improvement in explicit memory
function due to increased choline supply and improved
cholinergic function.
A poor folate status is associated with cognitive de-
cline and dementia in older adults [48]. Although im-
paired brain methylation activity and HCy toxicity are
widely thought to account for this association, how fol-
ate deficiency impairs cognition is still uncertain. Troen
et al. [49] found a correspondence of cognitive outcomes
to changes in brain membrane PC content (in rats),
which suggests that altered PC and possibly choline me-
tabolism might contribute to the manifestation of folate
deficiency-related cognitive dysfunction. Up to 50% of
older people have been reported to have folate deficiency,
with higher levels in those institutionalized [50]. For this
reason, there is a sound theoretical reasoning to speculate
on a positive beneficial outcome in relation to cognition
and boosting memory with choline and choline-containing
compounds [44].
Elevated total homocysteine (tHcy), a risk factor for
many chronic diseases including cognitive decline, can
be remethylated to methionine by folate [51]. Alternatively,
tHcy can be metabolized by other 1-carbon nutrients, that
is, betaine and its precursor, choline. Elias et al. [48] re-
ported that tHcy levels are inversely associated with visual-
spatial organization, working memory, scanning-tracking,
and abstract reasoning. Chiuve et al. [52] assessed the asso-
ciation between the dietary intakes of betaine and choline
and the concentration of tHcy. They found the total cho-
line + betaine intake to be inversely associated with tHcy.
In a double-blind, placebo-controlled clinical trial Olthof
et al. [53] investigated the supplementation with soybean
PC (PhosChol) on homocysteine plasma concentrations
in men with mildly elevated levels. They found that PC
was able to reduce homocysteine levels, thus supporting
the link between dietary intake of PC and homocysteine
plasma levels.
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Gangliosides
Brain content of specific gangliosides (for example, GM1)
has been documented to decrease with age, and a low
GM1 content has been observed in the brains of patients
with AD [54]. Exogenously administered gangliosides have
been shown to exhibit neurotrophic action, and to in-
crease the release of brain-derived neurotrophic factor
(BDNF) in vitro [55]. Experimental data have shown that
gangliosides, and in particular, GM1, exhibit properties
similar to the neurotrophins. The neurotrophins promote
neurogenesis, which is essential for specific cognitive func-
tions that decline in some neurological disorders and in
ageing [56]. A systemic administration of GM1 in rats
ameliorated the age-related decreased activity of choline
acetyl transferase and choline uptake in the brain of aged
rats as well as improved spatial learning and memory tasks
in the aged rats [57]. Dietary gangliosides increase total
brain-ganglioside content in rats [58].
Sphingomyelin (SM)
The myelin content of the brain decreases with age and
the age-related slowing in cognitive processing speed is
associated with myelin integrity in a very healthy elderly
population [59]. Dietary bovine SM contributes to cen-
tral nervous system (CNS) myelination [60]. Sphingo-
myelin is also a source of choline. Clinical trials are yet
to be conducted in order to assess the in vivo neurocog-
nitive effects of SM in humans.
Methods/Design
Phospholipid intervention for cognitive ageing rever-
sal (PLICAR) is a randomized, double-blind, placebo-
controlled, three-arm, stratified parallel-groups clinical
trial with participants randomized to receive a minimum
daily dosage of 2.7 g phospholipids (and minimum daily
dose of 300 mg/day PS) from Lacprodan® PL-20 or one of
two placebos (milk protein concentration or rice starch)
over a 180-day (6-month) period. The maximum daily
dose of Lacprodan® PL-20 will be 16 g/day. Participants
will be stratified according to age, IQ using Raven’s
Progressive Matrices (RPM) [61] and baseline score on
the Wechlser Memory Scale-Revised (WMS-R) [62].
Aims and study hypotheses
The primary objective of the current study is to evaluate
the chronic effects of daily Lacprodan® PL-20 supple-
mentation on cognitive performance in a healthy elderly
population with age-associated memory impairment
(AAMI). The secondary objectives of the study are to in-
vestigate mood and CV effects of Lacprodan® PL-20 as well
as the in vivo mechanisms of action by which Lacprodan®
PL-20 may improve cognitive function. To this end, a
range of measurement modalities will be employed in-
cluding assessments of CV function, blood biomarkers,
gastrointestinal (GI) microbiota, pharmacogenomics and
brain activity assessed by functional magnetic resonance
imaging (fMRI), magnetoencephalography (MEG) and dif-
fusion tensor imaging (DTI).
Performance on the various outcome measures for par-
ticipants receiving Lacprodan® PL-20 will be compared
to the performance of participants receiving (i) an inert
placebo powder made of rice starch, and (ii) a milk-
protein concentrate without phospholipids that has been
matched for protein content and total calories. The rea-
son/rationale for including two comparator treatments
(rather than one) is the opportunity to address separ-
ate research questions. The first comparison (to inert
placebo) addresses the research question of whether
Lacprodan® PL-20 as a whole has benefits for cognitive
function and other secondary outcomes. The second
comparison to a milk-protein concentrate without phos-
pholipids addresses a more specific research question re-
garding whether benefits to cognition and other outcomes
associated with Lacprodan® PL-20 can be attributed specif-
ically to the phospholipid content in the formula. In con-
sideration of previous research demonstrating cognitive
benefits associated with dairy components other than
phospholipids [3], the inclusion of a third treatment arm
was deemed necessary in order to properly delineate the
effects of phospholipids versus other dairy components
present in Lacprodan® PL-20.
On the basis of previous human clinical studies with
bovine and plant-derived phospholipids, it is hypothesised
that in comparison to the inert placebo, Lacprodan® PL-20
supplementation over 180 days will result in significant
improvements on our primary variable, namely a com-
posite memory score computed from the Rey’s Verbal
Learning Test (RVLT). We are also exploring the pos-
sibly that the treatment may benefit other elements of
cognitive performance (including processing speed and
global functioning). A second hypothesis is that cogni-
tive benefits of a lesser magnitude will be observed when
comparing supplementation with Lacprodan® PL-20 with
milk protein concentrate (MPC) without phospholipids
placebo over 180 days. Additionally we are exploring
the effects of Lacprodan® PL-20 on a number of central,
CV and GI biomarkers.
Study site
PLICAR will be conducted at the Centre for Human
Psychopharmacology, Swinburne University of Technology,
Melbourne, Australia.
Participants
A total of 150 healthy elderly participants (≥55 years)
with AAMI will take part in the study. AAMI is defined
on the basis of criteria first outlined by Crook et al.
[63,64]: (i) a score >25 on the Memory Complaint
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Questionnaire (MAC-Q [64]) and (ii) a score ≤1 stand-
ard deviation below the mean for healthy young adults
on the paired associates test from the WMS-R [62]. Par-
ticipants will be excluded from participation if they are
currently diagnosed with dementia and/or score <24 on
the MMSE [65]; have a neurological, cardiac, endocrine,
GI or bleeding disorder; have a psychiatric illness, in-
cluding moderate-to-severe depression, as defined as a
score ≥20 on the Beck Depression Inventory II (BDI-II)
[66]; have a current or previous history of alcoholism
and/or substance abuse; have a known or suspected al-
lergy to cow’s milk and/or lactose intolerance; are a
current smoker, or are not fluent in the English language.
To be eligible, participants also cannot be currently taking
any medications or herbal/dietary supplements with
known cognitive effects. The study is jointly funded by
Arla Foods (Denmark) and Swinburne University of
Technology. It was ethically approved by the Swinburne
University Human Research Ethics Committee (pro-
ject number 2012/294) and all participants will provide
written informed consent. The trial has been registered
with the Australian and New Zealand Clinical Trials
Registry (ACTRN12613000347763).
Procedure
Eligible participants are required to attend four testing
sessions. An overview of the testing sessions is provided
in the clinical trial flow chart (Figure 1).
Visit 1 (screening/practice)
During the first visit, voluntary written informed consent
is obtained from all participants. Then the participants
are further screened for eligibility and administered
the MMSE, MAC-Q, WMS-R and BDI-II. A detailed
medical history is also taken, a dietary questionnaire is
administered [67,68] and demographic information is
collected, which includes body mass index (BMI), age,
educational background and general intelligence (as
measured by RPM). All eligible participants are then
required to complete practice versions of all the cognitive
outcome measures to be used in the study.
Visit 2 (Baseline)
The second visit will be scheduled for one week follow-
ing the screening/practice visit. In preparation for the
baseline visit, all participants will be required to collect
and store their faecal sample (as per the procedure pro-
vided in the faecal sample collection kit) a day before
the actual visit. The faecal sample for GI microbiota ana-
lysis will be deposited at the Centre for Human Psycho-
pharmacology, Swinburne University, when the participant
comes for the baseline visit. The faecal samples will be
stored at -80°C until further analysis. Also in preparation,
participants will be required to fast from 10 pm the night
before. A fasting blood sample will then be taken in order
to assess the baseline biochemical measures, together with
a separate blood sample, which will be used for Apolipo-
protein E (APOE) and Methylenetetrahydrofolate reductase
(MTHFR) genotyping. Following the blood samples, partic-
ipants will eat a light breakfast. Half an hour after break-
fast, participants will be required to complete all pre-dose
cognitive, mood and CV measures. Participants will then
be randomized to their treatment group (Lacprodan
PL-20® or MPC or rice starch) and consume their first sa-
chet of study treatment dissolved in water. A lunch break
of 90 minutes will then follow, before post dose testing
on all cognitive, mood and cardiovascular measures. At
the conclusion of the baseline study visit, participants will
be provided with enough study treatment for the next
90 days.
Visits 3 and 4 (90 and 180 days)
The schedule of events for the 90-day and 180-day visits
is identical to that for the baseline visit. On the day of
each study visit participants will be required to wait until
the completion of pre-dose assessments before consum-
ing their daily study treatment.
Neuroimaging sub-study
Participants involved in the neuroimaging sub-study will
be required to attend two additional sessions, the first in
the week preceding their baseline visit and the second in
the week preceding their 180-day visit (see Figure 1).
In the second visit they will be required to consume
their study treatment as usual in the morning before the
scans. This is due to the fact that the neuroimaging
sub-study is only concerned with the chronic effects of
PL-20 on brain function.
Sample size
Based on the reviewed literature, we predict a small-
medium effect size (f = 0.14) on the primary variable.
The sample size for this study is 150 participants, with
50 participants in each treatment group (Lacprodan®
PL-20, MPC or rice starch). Allowing for a 20% drop-out
rate over the course of the 180-day testing period, this
will give 80% power to detect significant treatment ×
time interactions from baseline to 180 days for the
primary outcome (calculated using G*Power 3.1, with
α = 0.05 and r = 0.5 for the correlation between repeated
measures).
Treatments
Lacprodan® PL-20, a powdered MPC rich in phos-
pholipids, is manufactured by Arla Foods Ingredients
Group P/S, Viby J, Denmark. The content of individ-
ual phospholipids in Lacprodan® PL-20 is displayed
in Table 1.
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Lacprodan® PL-20 will be administered orally at a max-
imum dose of 16 g/day, providing minimum daily dosages of
2.7 g PL and 300 mg PS. The powder is dissolved in 150 to
200 mL water and drunk once per day with breakfast. Two
placebo treatments will also be administered: (i) an inert
placebo consisting of rice starch (20 g/day), and (ii) an MPC
without phospholipids (Arla Foods); (12 g/day). Both placebo
treatments are also administered orally as powders dissolved
in ≤250 mL water and matched to Lacprodan® PL-20 for
colour and taste in order to ensure treatment blinding.
Figure 1 Phospholipid intervention for cognitive ageing reversal (PLICAR) protocol flow diagram. AAMI, age-associated memory
impairment; MAC-Q, Memory Complaint Questionnaire; MMSE, Mini Mental State Examination; BDI-II, Beck Depression Inventory II; BMI,
body mass index; RPM, Raven’s Progressive Matrices; APOE, Apoliprotein E; MTHFR, Methylenetetrahydrofolate reductase; MRI, magnetic
resonance imaging; MEG, magnetoencephalography; MPC, milk protein concentrate; TICS-M telephone interview for cognitive
status modified.
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Randomization and safety
Randomization of participants to treatment groups will
be determined by random allocation. For the neuroim-
aging sub-study 60 randomization numbers will be set
aside, which correspond to 10 female participants
receiving Lacprodan® PL-20, 10 receiving MPC and
10 receiving rice starch placebo, and 10 male partici-
pants receiving Lacprodan® PL-20, 10 receiving MPC
and 10 receiving rice starch placebo. Blinding for
both the main study as well as the neuroimaging
sub-study will be conducted by an independent staff
member at the Centre for Human Psychopharma-
cology, who is outside of the project, to code the
treatments, and maintain the key to this code until
data collection is completed. All potential adverse
events will be monitored throughout the trial, with
oversight from the Swinburne University of Technology
Human Research Ethics committee.
Primary outcomes
The primary study outcome is the effect of Lacprodan®
PL-20 supplementation on memory as measured using a
compound score from the RVLT [69,70], similar to that
used previously [71]. The memory score will be derived
using the formula:

Z15‐Word Learning test ‘total immediate recall’
þZ15‐Word Learning Test ‘maximum immediate recall’
þZ15‐Word Learning Test ‘delayed recall’Þ=3:
The RVLT is a test of verbal learning and memory that
has a long history of use both in the assessment of
clinical memory disturbances as well as cognitive decline
associated with normal ageing [70]. Verbal learning, as
measured by the RVLT and similar tests, has previously
been found to be sensitive to the effects of phospholipid
interventions in AAMI populations [39,41]. Similarly,
verbal memory has also been found to be sensitive to
other nutraceutical interventions such as Bacopa monnieri
[72] and folic acid [71] in elderly populations. For these
reasons, the inclusion of the RVLT will enable direct com-
parison of the efficacy of the milk-derived phospholipids
present in Lacprodan® PL-20 to previous cognitive inter-
vention studies in the elderly.
Secondary outcomes
A range of secondary outcomes will be used, encompass-
ing cognitive performance, mood, CV, GI microbiota, bio-
chemical, genetic and brain imaging modalities. Secondary
outcomes will include other elements of cognitive per-
formance as measured by a battery of well-validated and
highly sensitive cognitive tests. Traditional paper-and-
pencil neuropsychological tests as well as computerized
tasks have been included. These tests will be implemented
at baseline, 90 days and 180 days (pre-dose) in order to
capture chronic effects. This battery will consist of the
MMSE [65], the Prospective and Retrospective Memory
Questionnaire (PRMQ) [73], RVLT [69,70], Spatial Work-
ing memory and Contextual Memory tasks from the
Swinburne University Computerized Cognitive Ageing
Battery (SUCCAB [74]), rapid visual information process-
ing (RVIP), serial 3 s and 7 s subtraction and the Hick’s re-
action time paradigm. In order to capture potential acute
cognitive effects associated with Lacprodan® PL-20 supple-
mentation, the SUCCAB tests, RVIP, serial 3 s and 7 s sub-
traction and Hick’s reaction time will also be administered
90 minutes post dose.
The MMSE [65] is a global measure of cognitive func-
tion that has been used extensively both as a diagnostic
tool for dementia screening as well as a cognitive out-
come measure for gauging the efficacy of chronic nutra-
ceutical interventions in elderly participants, for example
[71,75,76]. The MMSE was included in the current study
due to its widespread use in previous research; however
problems with ceiling effects and insensitivity to change
amongst high-functioning individuals have been previ-
ously well-documented [77].
The PRMQ [73] is a self-report instrument which pro-
vides a measure of retrospective as well as prospective
memory slips in everyday life. The PRMQ was included
in the current study in order to provide an ecologically
valid measure of typical memory complaints that may be
of concern to elderly individuals. Although most memory
complaint questionnaires focus exclusively on failures to
remember previous information (retrospective memory),
the PRMQ is unique in that it additionally provides a
measure of prospective memory failures, which are failures
relating to tasks that need to be completed at a certain
time (for example, remembering to turn up to an appoint-
ment on time) [73,78].
In addition to the use of traditional psychometric tests,
the importance of including computerized tests that may
accurately gauge the speed of well-differentiated cogni-
tive functions has emerged in recent years [79]. In the
Table 1 Phospholipid composition of Lacprodan® PL-20
by percentage and daily dose
Percentage (%) Minimum dose
per day
Sphingomyelin 4.3 688 mg
Phosphatidyl choline (PC) 4.3 688 mg
Phosphatidyl serine (PS) 1.9 304 mg
Phosphatidyl ethanolamine (PE) 3.5 560 mg
Phosphatidyl inositol (PI) 1.3 208 mg
Ganglioside and others 0.7 112 mg
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current study the spatial working memory and context-
ual memory tasks from the SUCCAB have been included
due to high degrees of sensitivity to the effects of ageing,
as measured using response times [74]. Similarly, signifi-
cant reductions in response times on both of these tasks
have previously been reported in older participants fol-
lowing chronic nutraceutical interventions [80,81]. For
the assessment of processing speed, the highly sensitive
Hick reaction time paradigm [82] will be used. For the
assessment of cognitive function during increased de-
mand, serial 3 s and serial 7 s subtraction will be assessed
together with the RVIP computerized measure of sus-
tained attention. Previous research from our laboratory
has found the serial subtraction and RVIP tasks to be
particularly sensitive to the acute effects of nutraceutical
interventions [83-86].
Mood
There is evidence to suggest that phospholipid supple-
mentation may have a positive effect on chronic stress
as well as mood. Mood improvements have been previ-
ously reported in a double-blind trial of PS in depressed
patients [87]. A number of studies have also demon-
strated that phospholipids may have anti-stress effects,
as demonstrated by lowered levels of adrenocorticotro-
pic hormone (ACTH), reduction in perceived stress rat-
ings in response to acute stress [88] and reduced cortisol
release in response to acute stress [89,90]. In relation to
milk-based phospholipids, it was recently demonstrated
that chronic supplementation may lead to increased
morning cortisol availability in chronically stressed men
[91] as well as a blunting of self-report stress ratings in
response to an acute stressor [43].
Chronic changes in mood over the course of the trial
will be assessed using the Depression, Anxiety and Stress
Scale (DASS) [92], the Profile of Mood States (POMS)
[93] and Bond-Lader visual analogue mood scales [94].
These measures will be administered at baseline, 90 and
180 days pre-dose. The Bond-Lader scales will addition-
ally be administered post dose at each study visit in
order to capture potential acute mood effects associated
with Lacprodan® PL-20 treatment. The Bond-Lader
scales have previously been used by our group in a
wide range of acute and chronic intervention studies,
and have been found to display excellent sensitivity to
subtle affective changes.
Cardiovascular assessment
There is evidence to suggest that increases in arterial
stiffness with ageing, which are reflected in measures of
blood flow velocity, may be a contributing factor in cogni-
tive decline [95,96]. Previous research suggests that milk
proteins may increase insulin secretion, as well as help to
reduce blood pressure and plasma cholesterol levels [3,97].
Further, high levels of B12 present in milk may also help to
lower HCy levels, which are a contributing factor to CV
disease [98]. In light of the fact that Lacprodan® PL-20 is
an MPC, it could be argued that chronic supplementation
may have a positive influence on CV function. By this
reasoning, the inclusion of CV parameters in the current
study will enable exploration of whether improvements to
CV function are a mechanism by which with Lacprodan®
PL-20 may achieve cognitive benefits.
CV function will be assessed using brachial blood pres-
sure, aortic blood pressure, carotid-femoral pulse wave
velocity (PWV) as well as blood flow velocity in the medial
carotid artery and the common carotid artery (CCA). Bra-
chial blood pressure will be calculated with the participant
seated and following a five-minute rest period using a
clinically validated automated sphygmomanometer. Aortic
blood pressure, pulse pressure and PWV (all aspects of
arterial stiffness and CV pressures) will be measured non-
invasively using the SphygmoCor device. Applanation
tonometry of the radial artery will be used to estimate aor-
tic pressures and wave reflections, and applanation of the
carotid and femoral arteries will be used to measure PWV.
A non-invasive transcranial Doppler system will be used
to record middle cerebral artery (MCA) blood velocity by
placing a sensor close to the participant’s ear and common
carotid artery (CCA) blood velocity will be recorded by
placing a hand-held sensor at the base of the participant’s
neck. All CV measures will be assessed pre- and post dose
at the baseline, 90-day and 180-day study visits in order to
capture both acute and chronic effects associated with
Lacprodan® PL-20 supplementation.
Gastrointestinal microbiota
In recent years research in the field of GI microbiota
has caught major interest. Research is suggesting that
modifications in the composition of the GI microbiota
influence normal physiological functions and contribute
to diseases ranging from inflammation to diabetes. Col-
lectively studies now indicate that the gut microbiota also
communicates with the CNS possibly through immune,
neural and endocrine pathways, and by these means
influences gut-brain communication, brain function and
even behaviour [99-101]. Studies on germ-free animals
and animals exposed to pathogenic bacterial infections,
probiotic bacteria or antibiotics, suggest a role of GI
microbiota in the regulation of cognition, anxiety and
mood [101-103]. Moreover GI microbiota perform many
important functions like protection, immune develop-
ment and metabolism, which together have an enormous
effect on host nutrition and health condition [104-106].
Previous studies suggest that human and bovine milk
proteins prevent the adhesion and colonisation of patho-
genic bacteria in the GI tract [107-109] and promote the
growth of beneficial bacteria [110]. As knowing that GI
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microbiota have several physiological functions in the hu-
man health condition, it can be influenced by Lacprodan®
PL-20 milk protein supplementation. Therefore, it will be
valuable to study the GI microbiota at different time
points across the clinical trial to identify the effect of
Lacprodan® PL-20 on indigenes microbial community.
Faecal samples will be collected for the GI microbiota
analysis at baseline, 90 days and 180 days to explore the
possible effect of Lacprodan® PL-20 on the microbial
composition. The microbiota analysis will be carried out
by utilising deep next-generation shotgun sequencing
[111] of DNA extracted from collected faecal samples.
This analysis will provide insight into GI microbiota of
the ageing population and also functional character-
isation will provide understanding of the potential mechan-
ism by which Lacprodan® PL-20 may influence age-related
cognitive decline (ARCD).
Biochemical assessment
Haematological testing will be conducted at baseline,
90 days and 180 days in order to further investigate pos-
sible mechanisms by which Lacprodan® PL-20 may influ-
ence cognitive decline. These measures have been chosen
on the basis of current aetiological understanding of brain
ageing as well as proposed in vivo actions of Lacprodan®
PL-20 constituents.
Previous research has demonstrated that administration
of PC, a major phospholipid component of Lacprodan®
PL-20, can increase the plasma choline as well as brain
acetylcholine (Ach) supply [112,113]. Further, elevated
levels of the neurotoxic substance HCy have been found
to be a risk factor for cognitive decline [48,114-116].
Improved HCy levels have been found to result from
increased intake of PC and choline [52,53]. Vitamin B12,
which is present in high quantities in dairy products [117],
has also been found to be effective in reducing HCy in eld-
erly populations [118]. For these reasons plasma choline
as well as B Vitamins and HCy levels will be monitored
throughout the study.
Other major contributors to brain ageing are oxidative
stress [119,120] and inflammation [121]. The phos-
pholipids PC and PS have both been found to display
anti-inflammatory and antioxidant properties, inhibiting
microglial activation as well as superoxide and nitric
oxide production [122]. Endogenous antioxidant glutathi-
one (GSH) is the most abundant antioxidant in human
cells, which plays a central role in defence from oxidative
stress [123]. Under normal physiological conditions the
ratio of reduced GSH to oxidized glutathione (glutathione
disulphide, GSSG) is as high as 100:1. However, in cases
of increased oxidative stress the ratio changes due to
increased levels of GSSG or decreased levels of reduced
GSH. For this reason peripheral blood levels of GSH as
well as the ratio of GSH/GSSG in the blood are good
measures of oxidative stress, and have been found to be al-
tered in patients with mild cognitive impairment and AD
[124]. Another widely-used biomarker of oxidative
stress is F2-isoprostane, which is an excellent in vivo
measure of lipid peroxidation [125]. Peripheral blood
plasma levels of F2 isoprostane have been found to be
significantly elevated in mild cognitive impairment
[126]. A previous study from our laboratory in elderly
participants found plasma F2 isoprostane levels to
significantly decline following a 3-month intervention
with the antioxidant Pycnogenol [127]. In addition to
these measures of oxidative stress, serum measures of in-
flammation will be provided using the following inflam-
matory biomarkers: TNF-α, IL-1β, IL-6 and C-reactive
protein (CRP). Peripheral levels of these inflammatory
biomarkers have previously been found to be elevated in
cases of mild cognitive impairment and AD in compari-
son to healthy age-matched controls [128,129].
Genetic
A separate blood sample will be collected pre-
randomization for the analysis of single nucleotide poly-
morphisms (SNP) in the APOE and the MTHFR genes.
The APOE-ε4 allele has been found to be associated with
an increased risk of developing AD as well as cognitive
decline in normal elderly [130,131]. Testing for allelic dif-
ferences in the APOE gene was included in the current
study in order to determine whether these genetic differ-
ences may affect the efficacy of Lacprodan® PL-20 as a
treatment for AAMI. MTHR is an important enzyme
involved in the metabolism of HCy. The MTHFR 677 T
allele is associated with reduced enzymatic activity, which
results in decreased serum and plasma levels of folate as
well as increased plasma levels of HCy [132]. In consider-
ation of the relationship between levels of phospholipids,
vitamin B12 and HCy [53,118], genetic testing for allelic
differences in the MTHFR gene was included in the
current study in order to assess whether this may also
affect the efficacy of Lacprodan® PL-20 as an AAMI
treatment.
Neuroimaging
Neuroimaging with fMRI and MEG will be conducted in
a subset of 60 participants in order to further explore
the in vivo mechanisms of action of Lacprodan® PL-20
in the brain. Previous neuroimaging studies using PS
supplementation in AD have been conducted using elec-
troencephalography (EEG) as well as positron emission
tomography (PET) [133-135]. PET results revealed that
for the PS group there was increased glucose metabol-
ism during a visual recognition task across a number of
brain regions, most notably the temperoparietal regions
[133]. However, to date no further neuroimaging studies
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have been conducted using phospholipid interventions,
and to the best of our knowledge none have been
conducted using MRI or MEG.
In the current study structural and functional MRI
scans will be acquired using a Siemens 3 Tesla Tim Trio
MRI scanner (Erlangen, Germany), located at the Centre
Table 2 Summary of PLICAR outcome measures by visit
Measures V1 V2 V3 V4
Screening Written informed consent X
Demographics X
Medical history X
Inclusion/exclusion criteria X X X X
Concomitant medications X X X X
Adverse events X X X X
Dietary questionnaire X
Cognitive Memory Complaint Questionnaire (MAC-Q) X
Wechsler Memory Scale Revised (WMS-R) X
Raven’s Progressive Matrices (RPM) X
Mini Mental State Exam (MMSE) X X X X
Rey Verbal Learning Test (RVLT) X X X X
SUCCAB Spatial Working Memory X X X X
SUCCAB Contextual Memory X X X X
Prospective and Retrospective Memory (PRMQ) X X X X
Rapid visual information processing (RVIP) X X X X
Serial 3 s and 7 s subtraction X X X X
Jensen box task X X X X
Mood Beck Depression Inventory (BDI-II) X
Depression, Anxiety and Stress Scale (DASS) X X X X
Profile of Mood States (POMS) X X X X
Bond-Lader visual analogue mood scales X X X X
Cardiovascular Brachial blood pressure X X X
SphygmoCor (Aortic blood pressure, pulse pressure, PWV) X X X
Blood velocity (MCA and CCA) X X X
GI microbiota Intestinal bacteria X X X
Biochemical Oxidative stress (Glutathione and F2 isoprostanes) X X X
Inflammation (TNF-α, IL-1β, IL-6 and CRP) X X X
B Vitamins (B6, B9 and B12) X X X
Homocysteine (HCy) X X X
Glucoregulation X X X
Serum choline X X X
Genetic Apolipoprotein E and MTHFR X
Brain imaging Structural magnetic resonance imaging (MRI) X X
Diffusion tensor imaging (MRI) X X
Default mode network activation (MEG and MRI) X X
Relaxometry (MRI) X X
Episodic Memory task (functional MRI and MEG) X X
N-Back working memory task (functional MRI and MEG) X X
V1, screening/practice session; V2, baseline visit; V3, 9-day visit; V4, 180-day visit; GI, gastrointestinal; SUCCAB, Spatial Working memory and Contextual Memory
tasks from the Swinburne University Computerized Cognitive Ageing Battery; PWV, pulse wave velocity; MCA, medial carotid artery; CCA, common carotid artery;
CRP, C-reactive protein; MTHFR, Methyltetrahydrofolate reductase; MEG, magnetoencephalography.
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for Human Psychopharmacology, Swinburne University
of Technology. During the initial scan, a structural
image will be obtained for each participant and used
as a reference point for further functional scans. Scan-
ning for DTI analysis, a measure of white matter integ-
rity, will also be conducted. Following DTI there will be
scanning in a resting state in order to assess activity
in the default mode network (DMN) for approximately
6 minutes. Additional analysis of cell membrane fluid-
ity will also be conducted by using the T2 signal tim-
ing information (relaxometry) while in a resting state.
Changes in the blood oxygenation-level dependent (BOLD)
signal will also be analysed while participants complete
in-scanner versions of verbal episodic memory (approxi-
mately 20 minutes) and N-Back working memory tasks
(approximately 20 minutes).
MEG scanning will be conducted using an Elekta
Neuromag® TRIUX 306-Channel Magnetometer system
(Helsinki, Finland) MEG system, also located at the
Centre for Human Psychopharmacology, Swinburne
University of Technology. Initial scanning while in a rest-
ing state will be conducted in order to collect informa-
tion as to activity in the DMN. Following this scanning
will be conducted whilst participants complete the same
in-scanner tasks as used in the fMRI task: verbal episodic
memory and N-Back working memory. The two tasks are
kept the same across both fMRI and MEG in order for
information from the two imaging modalities to be com-
bined into a single comprehensive analysis. MEG scan-
ning provides important complementary information,
which is additional to that provided by fMRI. The tem-
poral resolution of MEG is far superior to fMRI; MEG is
capable of recording neural oscillations from delta right
through to the gamma range (>40 Hz). Although the
spatial resolution of MEG is less than that of fMRI, the
high number of sensors (approximately 300), together
with modern source reconstruction algorithms (for ex-
ample, beam forming) means that the spatial resolution
of MEG is far superior to conventional scalp-recorded
EEG [135]. The combination of the two imaging modal-
ities is state-of-the-art and will provide an unparalleled
level of analysis of the effects of Lacprodan® PL-20 on
memory function.
All primary and secondary outcome measures are
displayed in Table 2.
Analysis
The primary analysis will investigate the effect of
treatment on all cognitive outcomes from baseline to
180 days, using the groups as randomized (intention to
treat). Statistical analyses will be conducted using linear
mixed modelling, whereby subject-specific random in-
tercepts and slopes will be fitted to subject data and
fixed effects will be fitted to treatment group, time and
the treatment × time interaction. On the basis of APOE
and MTHFR genotyping, subgroup analysis will also be
conducted in order to investigate the effect of allelic
differences on treatment response. Secondary outcome
variables will be analysed using similar statistical tech-
niques. Results will be considered statistically signifi-
cant at an alpha level of P <0.05 corrected for multiple
comparisons.
Although stratification according to age, intelligence
and baseline WMS-R scores may help to explain some
of the residual between-group variance unrelated to the
treatment effect, further exploration of possible covari-
ates will also be investigated. Baseline correlations be-
tween the primary cognitive outcome measures and
other baseline variables, including BMI, educational
background, diet, CV function, GI microbiota and bio-
chemical parameters, will also be investigated in order
to investigate other important covariates. In the event
that significant correlations at the P <0.05 level are
found at baseline then these additional variables will
also be controlled for in the primary analysis of cogni-
tive outcomes.
Analysis of functional neuroimaging data (both MEG
and fMRI) during episodic memory and N-Back working
memory tasks will be conducted using a region of inter-
est (ROI) approach. Using this method, between-group
(Lacprodan® PL-20 versus MPC and inert placebo) func-
tional differences in predefined brain regions will be
statistically analysed. The ROIs for the episodic memory
task will include the medial temporal lobes, the lateral
prefrontal cortices, the associative temporal and paretial
regions, the cingulate gyrus and the cerebellum. The
ROIs that will be analysed in the N-Back working memory
task will include the dorsolateral, ventrolateral and medial
prefrontal cortex, anterior cingulate, parietal cortex and
sensorimotor cortex [136].
Trial status
The trial is currently recruiting.
Abbreviations
AAMI: Age-associated memory impairment; AD: Alzheimer’s disease;
APOE: Apolipoprotein E; ARCD: Age-related cognitive decline; BDI-II: Beck
depression inventory II; BMI: Body mass index; CCA: Common carotid artery;
CNS: Central nervous system; CRP: C-reactive protein; V: Cardiovascular;
DASS: Depression anxiety and stress scale; DNM: Default mode network;
DTI: Diffusion tensor imaging; EEG: Electroencephalography; fMRI: Functional
magnetic resonance imaging; GI: Gastrointestinal; GSH: Glutathione;
GSSG: Glutathione disulphide; HCy: Homocysteine; L: Interleukin;
MAC-Q: Memory complaint questionnaire; MCA: Middle cerebral artery;
MEG: Magnetoencephalography; MPC: Milk protein concentrate;
MTHFR: Methylenetetrahydrofolate reductase; MSE: Mini mental state
Examination; PC: Phosphatidylcholine; PET: Positron emission tomography;
PL: Phospholipid; PLICAR: Phospholipid intervention for cognitive ageing
reversal; POMS: Profile of mood states; PRMQ: Prospective and retrospective
memory questionnaire; PS: Phosphatidylserine; PWV: Pulse wave velocity;
ROI: Region of interest; RPM: Raven’s progressive matrices; RVIP: Rapid visual
information processing; RVLT: Rey’s verbal learning test; SB: Soybean;
SUCCAB: Spatial working memory and contextual memory tasks from the
Scholey et al. Trials 2013, 14:404 Page 11 of 15
http://www.trialsjournal.com/content/14/1/404
Swinburne university computerized cognitive ageing battery; tHcy: Total
homocysteine; TICS-M: Telephone interview for cognitive status – modified;
TNF: Tumour necrosis factor; WMS-R: Wechlser memory scale-revised.
Competing interests
AS and CS receive research funding from the food industry, PF is an
employee of Arla Foods. The other authors declare that they have no
competing interests.
Authors’ contributions
AS conceived the study, participated in its design and contributed to
drafting the manuscript, DC developed the study design and drafted the
manuscript, MH conceived and has responsibility for the fMRI component of
the study, WW conceived and has responsibility for the MEG component of
the study, CS participated in the study design and contributed to the
manuscript, DW participated in the study design and contributed to the
manuscript, SG developed the protocol and has responsibility for the
microbiota component of the study, PF participated in the study design and
contributed to the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This study is funded by Arla Foods, Denmark. Author PF is an employee of
Arla Foods and contributed to the study design and to the manuscript.
Author details
1Centre for Human Psychopharmacology, Swinburne University of
Technology, Melbourne 3122, Victoria, Australia. 2Brain & Psychological
Sciences Research Centre, Swinburne University of Technology, Melbourne,
Australia. 3Arla Food Ingredients, P/S Sønderhøj 14, 8260, Viby J, Denmark.
Received: 17 July 2013 Accepted: 11 November 2013
Published: 26 November 2013
References
1. Salthouse TA, Meinz EJ: Aging, inhibition, working memory, and speed.
J Gerontol B Psychol Sci Soc Sci 1995, 50:297–306.
2. Reid LM, MacLullich AMJ: Subjective memory complaints and cognitive
impairment in older people. Dement Geriatr Cogn Disord 2006, 22:471–485.
3. Camfield DA, Owen L, Scholey AB, Pipingas A, Stough C: Dairy constituents
and neurocognitive health in ageing. Br J Nutr 2011, 106:159–174.
4. Segura B, Jurado Luque MÁ: Metabolic syndrome and ageing: cognitive
impairment and structural alterations of the central nervous system
[article in Spanish]. Rev Neurol 2009, 49:417–424.
5. Crichton GE, Bryan J, Buckley J, Murphy KJ: Dairy consumption and
metabolic syndrome: a systematic review of findings and
methodological issues. Obes Rev 2011, 12:e190–e201.
6. Crichton GE, Elias MF, Dore GA, Robbins MA: Relation between dairy food
intake and cognitive function: the Maine-Syracuse longitudinal study. Int
Dairy J 2012, 22:15–23.
7. Kidd PM: Phosphatidylserine; membrane nutrient for memory. a clinical
and mechanistic assessment. Altern Med Rev 1996, 1:70–84.
8. Toffano G, Battistella A, Orlando P: Pharmacokinetics of radiolabelled brain
phosphatidylserine. Clin Trials J 1987, 24:18–24.
9. Salem N Jr, Serpentino P, Puskin JS, Abood LG: Preparation and
spectroscopic characterization of molecular species of brain
phosphatidylserines. Chem Phys Lipids 1980, 27:289–304.
10. Pepeu G, Pepeu IM, Amaducci L: A review of phosphatidylserine
pharmacological and clinical effects. Is phosphatidylserine a drug for the
ageing brain? Pharmacol Res 1996, 33:73–80.
11. Kidd PM: Alzheimer’s disease, amnestic mild cognitive impairment, and
age-associated memory impairment: current understanding and pro-
gress toward integrative prevention. Altern Med Rev 2008, 13:85–115.
12. Osella MC, Re G, Badino P, Bergamasco L, Miolo A: Phosphatidylserine (PS)
as a potential nutraceutical for canine brain aging: a review. J Vet Behav:
Clin Appl Res 2008, 3:41–51.
13. Vannucchi MG, Casmenti F, Pepeu G: Decrease of acetylcholine release
from cortical slices in aged rats: investigations into its reversal by
phosphatidylserine. J Neurochem 1990, 55:819–825.
14. Vannucchi MG, Pepeu G: Effect of phosphatidylserine on acetylcholine
release and content in cortical slices from aging rats. Neurobiol Aging
1987, 8:403–407.
15. Zanotti A, Valzelli L, Toffano G: Chronic phosphatidylserine treatment
improves spatial memory and passive avoidance in aged rats.
Psychopharmacology (Berl) 1989, 99:316–321.
16. Argentiero V, Tavolato B: Dopamine (DA) and serotonin metabolic levels
in the cerebrospinal fluid (CSF) in Alzheimer’s presenile dementia under
basic conditions and after stimulation with cerebral cortex phospholipids
(BC-PL). J Neurol 1980, 224:53–58.
17. Bruni A, Toffano G, Leon A, Boarato E: Pharmacological effects of
phosphatidylserine liposomes. Nature 1976, 260:331–333.
18. Milan F, Guidolin D, Polato P: Structural changes of basal forebrain
cholinergic neurons in the aged rat. Effect of phosphatidylserine
administration. In New Trends in Aging Research. Edited by Pepeu G,
Tomlinson B, Wischik CM. Padova, Italy: Liviana Press; 1988:221–231.
19. Gelbmann CM, Muller WE: Chronic treatment with phosphatidylserine
restores muscarinic cholinergic receptor deficits in the aged mouse
brain. Neurobiol Aging 1992, 13:45–50.
20. Nunzi MG, Milan F, Guidolin D, Polato P, Toffano G: Effects of
phosphatidylserine administration on age-related structural changes
in the rat hippocampus and septal complex. Pharmacopsychiatry, Suppl
1989, 22:125–128.
21. Nunzi MG, Guidolin D, Petrelli L, Polato P, Zanotti A: Behavioral and
morpho-functional correlates of brain aging: a preclinical study with
phosphatidylserine. Adv Exp Med Biol 1992, 318:393–398.
22. Suzuki S, Furushiro M, Takahashi M, Sakai M, Kudo S: Oral administration of
soybean lecithin transphosphatidylated phosphatidylserine (SB-tPS)
reduces ischemic damage in the gerbil hippocampus. Jpn J Pharmacol
1999, 81:237–239.
23. Calderini G, Aporti F, Bonetti AC: Pharmacological effect of
phosphatidylserine on age-dependent memory dysfunction. Ann NY
Acad Sci 1985, 444:504–506.
24. Hashioka S, Han YH, Fujii S, Kato T, Monji A, Utsumi H, Sawada M, Nakanishi H,
Kanba S: Phosphatidylserine and phosphatidylcholine-containing liposomes
inhibit amyloid Beta and interferon-gamma-induced microglial activation.
Free Radic Biol Med 2007, 42:945–954.
25. Suzuki S, Yamatoya H, Sakai M, Kataoka A, Furushiro M, Kudo S: Oral
administration of soybean lecithin transphosphatidylated
phosphatidylserine improves memory impairment in aged rats.
J Nutr 2001, 131:2951–2956.
26. Valzelli L, Kozak W, Zanotti A, Toffano G: Activity of phosphatidylserine on
memory retrieval and on exploration in mice. Methods Find Exp Clin
Pharmacol 1987, 9:657–660.
27. Zanotti A, Aporti F, Toffano G, Valzelli L: Effects of phosphatidylserine on
avoidance relearning in rats (preliminary observations). Pharmacol Res
Commun 1984, 16:485–493.
28. Claro FT, Patti CL, Abilio VC, Frussa-Filho R, Silva RH: Bovine brain
phosphatidylserine attenuates scopolamine induced amnesia in
mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2006, 30:881–886.
29. Furushiro M, Suzuki S, Shishido Y, Sakai M, Yamatoya H, Kudo S, Hashimoto S,
Yokokura T: Effects of oral administration of soybean lecithin
transphosphatidylated phosphatidylserine on impaired learning of
passive avoidance in mice. Jpn J Pharmacol 1997, 75:447–450.
30. Zanotti A, Valzelli L, Toffano G: Reversal of scopolamine-induced amnesia
by phosphatidylserine in rats. Psychopharmacology (Berl) 1986, 90:274–275.
31. Vaisman N, Pelled D: n - 3 phosphatidylserine attenuated scopolamine-
induced amnesia in middle-aged rats. Prog Neuro-Psychopharmacol Biol
Psychiatry 2009, 33:952–959.
32. Alves CSD, Andreatini R, da Cunha C, Tufik S, Vital MABF: Phosphatidylserine
reverses reserpine-induced amnesia. Eur J Pharmacol 2000, 404:161–167.
33. Amaducci L, Group S: Phosphatidylserine in the treatment of Alzheimer’s
disease: results of a multicenter study. Psychopharmacol Bull 1988,
24:130–134.
34. Crook T, Petrie W, Wells C, Massari DC: Effects of phosphatidylserine in
Alzheimer’s disease. Psychopharmacol Bull 1992, 28:61–66.
35. Delwaide PJ, Gyselynck-Mambourg AM, Hurlet A, Ylieff M: Double-blind
randomized controlled study of phosphatidylserine in senile demented
patients. Acta Neurol Scand 1986, 73:136–140.
36. Engel RR, Satzger W, Günther W, Kathmann N, Bove D, Gerke S, Münch U,
Hippius H: Double-blind cross-over study of phosphatidylserine vs.
Scholey et al. Trials 2013, 14:404 Page 12 of 15
http://www.trialsjournal.com/content/14/1/404
placebo in patients with early dementia of the Alzheimer type.
Eur Neuropsychopharmacol 1992, 2:149–155.
37. Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G: Cognitive decline in
the elderly: a double-blind, placebo-controlled multicenter study on
efficacy of phosphatidylserine administration. Aging Clin Exp Res 1993,
5:123–133.
38. Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC: Effects
of phosphatidylserine in age-associated memory impairment. Neurology
1991, 41:644–649.
39. Villardita C, Grioli S, Salmeri G: Multicentre clinical trial of brain
phosphatidylserine in elderly patients with intellectual deterioration.
Clin Trials J 1987, 24:84–93.
40. Jorissen BL, Brouns F, van Boxtel MPJ, Ponds RWHM, Verhey FRJ, Jolles
J, Riedel WJ: The influence of soy-derived phosphatidylserine on
cognition in age-associated memory impairment. Nutr Neurosci 2001,
4:121–134.
41. Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD: Phosphatidylserine
containing ω-3 fatty acids may improve memory abilities in non-demented
elderly with memory complaints: a double-blind placebo-controlled trial.
Dement Geriatr Cogn Disord 2010, 29:467–474.
42. Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T: Soybean-
derived phosphatidylserine improves memory function of the elderly
Japanese subjects with memory complaints. J Clin Biochem Nutr 2010,
47:246–255.
43. Hellhammer J, Waladkhani AR, Hero T, Buss C: Effects of milk phospholipid
on memory and psychological stress response. Br Food J 2010,
112:1124–1137.
44. McDaniel MA, Maier SF, Einstein GO: “Brain-specific” nutrients: a memory
cure? Nutrition 2003, 19:957–975.
45. Zeisel SH, da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF,
Beiser A: Choline, an essential nutrient for humans. FASEB J 1991,
5:2093–2098.
46. Nagata T, Yaguchi T, Nishizaki T: DL- and PO-phosphatidylcholines as a
promising learning and memory enhancer. Lipids Health Dis 2011, 10:25.
47. Ladd SL, Sommer SA, LaBerge S, Toscano W: Effect of phosphatidylcholine
on explicit memory. Clin Neuropharmacol 1993, 16:540–549.
48. Elias MF, Robbins MA, Budge MM, Elias PK, Brennan SL, Johnston C, Nagy Z,
Bates CJ: Homocysteine, folate, and vitamins B6 and B12 blood levels in
relation to cognitive performance: The Maine-Syracuse study.
Psychosom Med 2006, 68:547–554.
49. Troen AM, Chao WH, Crivello NA, D’Anci KE, Shukitt-Hale B, Smith DE,
Selhub J, Rosenberg IH: Cognitive impairment in folate-deficient rats
corresponds to depleted brain phosphatidylcholine and is prevented by
dietary methionine without lowering plasma homocysteine. J Nutr 2008,
138:2502–2509.
50. Ahmed T, Haboubi N: Assessment and management of nutrition in
older people and its importance to health. Clin Interv Aging 2010,
5:207–216.
51. Haan MN, Miller JW, Aiello AE, Whitmer RA, Jagust WJ, Mungas DM, Allen LH,
Green R: Homocysteine, B vitamins, and the incidence of dementia and
cognitive impairment: results from the Sacramento Area Latino Study on
Aging. Am J Clin Nutr 2007, 85:511–517.
52. Chiuve SE, Giovannucci EL, Hankinson SE, Zeisel SH, Dougherty LW, Willett WC,
Rimm EB: The association between betaine and choline intakes and the
plasma concentrations of homocysteine in women. Am J Clin Nutr 2007,
86:1073–1081.
53. Olthof MR, Brink EJ, Katan MB, Verhoef P: Choline supplemented as
phosphatidylcholine decreases fasting and postmethionine-loading
plasma homocysteine concentrations in healthy men. Am J Clin Nutr
2005, 82:111–117.
54. Svennerholm L, Boström K, Jungbjer B, Olsson L: Membrane lipids of adult
human brain: lipid composition of frontal and temporal lobe in subjects
of age 20 to 100 years. J Neurochem 1994, 63:1802–1811.
55. Lim ST, Esfahani K, Avdoshina V, Mocchetti I: Exogenous gangliosides increase
the release of brain-derived neurotrophic factor. Neuropharmacology 2011,
60:1160–1167.
56. Glorioso C, Sibille E: Between destiny and disease: genetics and molecular
pathways of human central nervous system aging. Prog Neurobiol 2011,
93:165–181.
57. Fong TG, Neff NH, Hadjiconstantinou M: GM1 ganglioside improves spatial
learning and memory of aged rats. Behav Brain Res 1997, 85:203–211.
58. Park EJ, Suh M, Ramanujam K, Steiner K, Begg D, Clandinin MT: Diet-
induced changes in membrane gangliosides in rat intestinal mucosa,
plasma and brain. J Pediatr Gastroenterol Nutr 2005, 40:487–495.
59. Lu PH, Lee GJ, Raven EP, Tingus K, Khoo T, Thompson PM, Bartzokis G:
Age-related slowing in cognitive processing speed is associated with
myelin integrity in a very healthy elderly sample. J Clin Exp Neuropsychol
2011, 33:1059–1068.
60. Oshida K, Shimizu T, Takase M, Tamura Y, Yamashiro Y: Effects of dietary
sphingomyelin on central nervous system myelination in developing
rats. Pediatr Res 2003, 53:589–593.
61. Raven J, Raven JC, Court JH: Standard progressive matrices. Oxford:
Psychology Press; 2000.
62. Wechsler D: Wechsler Memory Scale - Revised. Sidcup, UK: The Psychological
Corporation, Harcourt Brace and Company; 1987.
63. Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, Gershon S:
Age-associated memory impairment: proposed diagnostic criteria and
measures of clinical change. Dev Neuropsychol 1986, 2:261–276.
64. Crook TH 3rd, Feher EP, Larrabee GJ: Assessment of memory complaint in
age-associated memory impairment: the MAC-Q. Int Psychogeriatr 1992,
4:165–176.
65. Folstein MF, Folstein SE, McHugh PR: Mini-mental state. A practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res 1975,
12:189–198.
66. Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inventory-II.
San Antonio, TX: Psychological Corporation; 1996.
67. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G: The Anti Cancer
Council of Victoria FFQ: relative validity of nutrient intakes compared
with weighed food records in young to middle-aged women in a study
of iron supplementation. Aust NZ J Public Health 2000, 24:574–583.
68. Giles C, Ireland P: Dietary Questionnaire for Epidemiological Studies (Version 2).
Cancer Council Victoria: Melbourne; 1996.
69. Rey A: L’examin clinique en psychologie. Paris, France: Presses Universitaires
de France; 1958.
70. van der Elst W, van Boxtel MPJ, van Breukelen GJP, Jolles J: Rey’s verbal
learning test: normative data for 1855 healthy participants aged 24–81 years
and the influence of age, sex, education, and mode of presentation. J Int
Neuropsychol Soc 2005, 11:290–302.
71. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P:
Effect of 3-year folic acid supplementation on cognitive function in older
adults in the FACIT trial: a randomised, double blind, controlled trial.
Lancet 2007, 369:208–216.
72. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B: Effects
of a standardized Bacopa monnieri extract on cognitive
performance, anxiety, and depression in the elderly: a randomized,
double-blind, placebo-controlled trial. J Altern Complement Med 2008,
14:707–713.
73. Crawford JR, Smith G, Maylor EA, Della Sala S, Logie RH: The Prospective
and Retrospective Memory Questionnaire (PRMQ): normative data
and latent structure in a large non-clinical sample. Memory 2003,
11:261–275.
74. Pipingas A, Harris E, Tournier E, King R, Kras M, Stough CK: Assessing the
efficacy of nutraceutical interventions on cognitive functioning in the
elderly. Curr Top Nutraceutical Res 2010, 8:79–87.
75. Gao Q, Niti M, Feng L, Yap KB, Ng TP: Omega-3 polyunsaturated fatty acid
supplements and cognitive decline: Singapore longitudinal aging
studies. J Nutr, Health and Aging 2011, 15:32–35.
76. Amieva H, Meillon C, Helmer C, Barberger-Gateau P, Dartigues JF: Ginkgo
biloba extract and long-term cognitive decline: a 20-year follow-up
population-based study. PLoS ONE 2013, 8:e52755.
77. Mungas D, Reed BR, Kramer JH: Psychometrically matched measures
of global cognition, memory, and executive function for assessment
of cognitive decline in older persons. Neuropsychology 2003,
17:380–392.
78. Smith G, Della Sala S, Logie RH, Maylor EA: Prospective and retrospective
memory in normal ageing and dementia: a questionnaire study. Memory
2000, 8:311–321.
79. Wesnes KA, Bullock R: The emerging importance of attention and the
speed of cognitive function in ageing and dementia research. CPD
Bulletin Old Age Psychiatry 2001, 3:11–15.
80. Harris E, MacPherson H, Vitetta L, Kirk J, Sali A, Pipingas A: Effects of a
multivitamin, mineral and herbal supplement on cognition and blood
Scholey et al. Trials 2013, 14:404 Page 13 of 15
http://www.trialsjournal.com/content/14/1/404
biomarkers in older men: a randomised, placebo-controlled trial. Hum
Psychopharmacol 2012, 27:370–377.
81. Pipingas A, Silberstein RB, Vitetta L, van Rooy C, Harris EV, Young JM,
Frampton CM, Sali A, Nastasi J: Improved cognitive performance after
dietary supplementation with a Pinus radiata bark extract formulation.
Phytother Res 2008, 22:1168–1174.
82. Jensen AR: The theory of intelligence and its measurement. Intelligence
2011, 39:171–177.
83. Scholey AB, Kennedy DO: Acute, dose-dependent cognitive effects of
Ginkgo biloba, Panax ginseng and their combination in healthy young
volunteers: differential interactions with cognitive demand.
Hum Psychopharmacol 2002, 17:35–44.
84. Scholey AB, French SJ, Morris PJ, Kennedy DO, Milne AL, Haskell CF:
Consumption of cocoa flavanols results in acute improvements in
mood and cognitive performance during sustained mental effort.
J Psychopharmacol 2010, 24:1505–1514.
85. Kennedy DO, Haskell CF, Mauri PL, Scholey AB: Acute cognitive effects of
standardised Ginkgo biloba extract complexed with phosphatidylserine.
Hum Psychopharmacol 2007, 22:199–210.
86. Reay JL, Kennedy DO, Scholey AB: Single doses of Panax ginseng (G115)
reduce blood glucose levels and improve cognitive performance during
sustained mental activity. J Psychopharmacol 2005, 19:357–365.
87. Maggioni M, Picotti GB, Bondiolotti GP, Panerai A, Cenacchi T, Nobile P,
Brambilla F: Effects of phosphatidylserine therapy in geriatric patients
with depressive disorders. Acta Psychiatr Scand 1990, 81:265–270.
88. Benton D, Donohoe RT, Sillance B, Nabb S: The influence of
phosphatidylserine supplementation on mood and heart rate when
faced with an acute stressor. Nutr Neurosci 2001, 4:169–178.
89. Monteleone P, Maj M, Beinat L, Natale M, Kemali D: Blunting by chronic
phosphatidylserine administration of the stress-induced activation of the
hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharmacol
1992, 42:385–388.
90. Hellhammer J, Fries E, Buss C, Engert V, Tuch A, Rutenberg D, Hellhammer D:
Effects of soy lecithin phosphatidic acid and phosphatidylserine complex
(PAS) on the endocrine and psychological responses to mental stress.
Stress 2004, 7:119–126.
91. Schubert M, Contreras C, Franz N, Hellhammer J: Milk-based phospholipids
increase morning cortisol availability and improve memory in chronically
stressed men. Nutr Res 2011, 31:413–420.
92. Lovibond PF, Lovibond SH: The structure of negative emotional states:
Comparison of the depression anxiety stress scales (DASS) with the Beck
Depression and Anxiety Inventories. Behav Res Ther 1995, 33:335–343.
93. McNair DM, Lorr M, Droppleman LF: Profile of mood states. Educational and
Industrial Testing Service: San Diego, CA; 1992.
94. Bond A, Lader M: The use of analogue scales in rating subjective feelings.
Br J Psychol 1974, 47:211–218.
95. Pase MP, Herbert A, Grima NA, Pipingas A, O’Rourke MF: Arterial stiffness as
a cause of cognitive decline and dementia: a systematic review and
meta-analysis. Intern Med J 2012, 42:808–815.
96. Pase MP, Pipingas A, Kras M, Nolidin K, Gibbs AL, Wesnes KA, Scholey AB,
Stough C: Healthy middle-aged individuals are vulnerable to cognitive
deficits as a result of increased arterial stiffness. J Hypertens 2010,
28:1724–1729.
97. Crichton GE, Howe PRC, Buckley JD, Coates AM, Murphy KJ: Dairy
consumption and cardiometabolic health: outcomes of a 12-month
crossover trial. Nutr Metab 2012, 9:34–40.
98. Refsum H, Ueland PM, Nygård O, Vollset SE: Homocysteine and
cardiovascular disease. Ann Rev Med 1998, 49:31–62.
99. Sekirov I, Russell SL, Antunes LCM, Finlay BB: Gut Microbiota in health and
disease. Physiol Rev 2010, 90:859–904.
100. Clemente Jose C, Ursell Luke K, Parfrey Laura W, Knight R: The impact of
the gut microbiota on human health: an integrative view. Cell 2012,
148:1258–1270.
101. Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, Hibberd ML,
Forssberg H, Pettersson S: Normal gut microbiota modulates brain
development and behavior. Proc Natl Acad Sci 2011, 108:3047–3052.
102. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu X-N, Kubo C, Koga Y:
Postnatal microbial colonization programs the hypothalamic–pituitary–
adrenal system for stress response in mice. J Physiol 2004, 558:263–275.
103. Cryan JF, O’Mahony SM: The microbiome-gut-brain axis: from bowel to
behavior. Neurogastroenterol Motil 2011, 23:187–192.
104. Cummings JH, Macfarlane GT: Role of intestinal bacteria in nutrient
metabolism. Clin Nutr 1997, 16:3–11.
105. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T, Tuckova L, Cukrowska B,
Lodinova-Zadnikova R, Kozakova H, Rossmann P, Bartova J, Sokol D, Funda DP,
Borovská D, Řeháková Z, Šinkora J, Hofman J, Drastich P, Kokešová A, et al:
Commensal bacteria (normal microflora), mucosal immunity and
chronic inflammatory and autoimmune diseases. Immunol Lett 2004,
93:97–108.
106. Wickens K, Black PN, Stanley TV, Mitchell E, Fitzharris P, Tannock GW, Purdie G,
Crane J: A differential effect of 2 probiotics in the prevention of eczema and
atopy: a double-blind, randomized, placebo-controlled trial. J Allergy Clin
Immunol 2008, 122:788–794.
107. Hancock JT, Salisbury V, Ovejero-Boglione MC, Cherry R, Hoare C, Eisenthal R,
Harrison R: Antimicrobial properties of milk: dependence on presence of
xanthine oxidase and nitrite. Antimicrob Agents Chemother 2002,
46:3308–3310.
108. Parker P, Sando L, Pearson R, Kongsuwan K, Tellam R, Smith S: Bovine Muc1
inhibits binding of enteric bacteria to Caco-2 cells. Glycoconj J 2010,
27:89–97.
109. Matsumoto M, Hara K, Kimata H, Benno Y, Shimamoto C: Exfoliation of
Helicobacter pylori from Gastric Mucin by Glycopolypeptides from
Buttermilk. J Dairy Sci 2005, 88:49–54.
110. Bode L: Human milk oligosaccharides: prebiotics and beyond. Nutr Rev
2009, 67:S183–S191.
111. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D,
Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y,
Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Wu R, Wang M, Feng Q, et al: A
metagenome-wide association study of gut microbiota in type 2 diabetes.
Nature 2012, 490:55–60.
112. Chung SY, Moriyama T, Uezu E, Uezu K, Hirata R, Yohena N, Masuda Y,
Kokubu T, Yamamoto S: Administration of phosphatidylcholine increases
brain acetylcholine concentration and improves memory in mice with
dementia. J Nutr 1995, 125:1484–1489.
113. Lee HC, Fellenz-Maloney MP, Liscovitch M, Blusztajn JK: Phospholipase
D-catalyzed hydrolysis of phosphatidylcholine provides the choline
precursor for acetylcholine synthesis in a human neuronal cell line.
Proc Natl Acad Sci USA 1993, 90:10086–10090.
114. Miller AL: The methionine-homocysteine cycle and its effects on cognitive
diseases. Altern Med Rev 2003, 8:7–19.
115. Mattson MP, Shea TB: Folate and homocysteine metabolism in neural
plasticity and neurodegenerative disorders. Trends Neurosci 2003,
26:137–146.
116. Elias MF, Sullivan LM, D’Agostino RB, Elias PK, Jacques PF, Selhub J, Seshadri S,
Au R, Beiser A, Wolf PA: Homocysteine and cognitive performance in the
Framingham Offspring Study: age is important. Am J Epidemiol 2005,
162:644–653.
117. US Department of Agriculture: USDA Nutrient Database for Standard Reference,
Release 16. Washington DC: Nutrient Data Laboratory Home Page; 2003.
118. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD: Cognitive and
clinical outcomes of homocysteine-lowering B-vitamin treatment in mild
cognitive impairment: a randomized controlled trial. Int J Geriatr
Psychiatry 2012, 27:592–600.
119. Halliwell B: Reactive oxygen species and the central nervous system.
J Neurochem 1992, 59:1609–1623.
120. Gracy RW, Talent JM, Kong Y, Conrad CC: Reactive oxygen species: the
unavoidable environmental insult? Mutat Res Fundam Mol Mech Mutagen
1999, 428:17–22.
121. Sarkar D, Fisher PB:Molecular mechanisms of aging-associated inflammation.
Cancer Lett 2006, 236:13–23.
122. Townsend DM, Tew KD, Tapiero H: The importance of glutathione in
human disease. Biomed Pharmacother 2003, 57:145–155.
123. Bermejo P, Martín-Aragón S, Benedí J, Susín C, Felici E, Gil P, Ribera JM, Villar AM:
Peripheral levels of glutathione and protein oxidation as markers in the
development of Alzheimer’s disease from Mild Cognitive Impairment. Free
Radic Res 2008, 42:162–170.
124. Mariani E, Polidori MC, Cherubini A, Mecocci P: Oxidative stress in brain
aging, neurodegenerative and vascular diseases: an overview.
J Chromatogr B Analyt Technol Biomed Life Sci 2005, 827:65–75.
125. Praticò D, Clark CM, Liun F, Lee VYM, Trojanowski JQ: Increase of brain
oxidative stress in mild cognitive impairment: a possible predictor of
Alzheimer disease. Arch Neurol 2002, 59:972–976.
Scholey et al. Trials 2013, 14:404 Page 14 of 15
http://www.trialsjournal.com/content/14/1/404
126. Ryan J, Croft K, Mori T, Wesnes K, Spong J, Downey L, Kure C, Lloyd J,
Stough C: An examination of the effects of the antioxidant Pycnogenol®
on cognitive performance, serum lipid profile, endocrinological and
oxidative stress biomarkers in an elderly population. J Psychopharmacol
2008, 22:553–562.
127. Guerreiro RJ, Santana I, Brás JM, Santiago B, Paiva A, Oliveira C: Peripheral
inflammatory cytokines as biomarkers in Alzheimer’s disease and mild
cognitive impairment. Neurodegener Dis 2007, 4:406–412.
128. Swardfager W, Lanctt K, Rothenburg L, Wong A, Cappell J, Herrmann N: A
meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry 2010,
68:930–941.
129. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH,
Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR,
Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD: Association of
apolipoprotein E allele ε4 with late-onset familial and sporadic
Alzheimer’s disease. Neurology 1993, 43:1467–1472.
130. Dik MG, Jonker C, Comijs HC, Bouter LM, Twisk JWR, van Kamp GJ, Deeg DJH:
Memory complaints and APOE-ε4 accelerate cognitive decline in cognitively
normal elderly. Neurology 2001, 57:2217–2222.
131. Brustolin S, Giugliani R, Félix TM: Genetics of homocysteine metabolism
and associated disorders. Braz J Med Biol Res 2010, 43:1–7.
132. Heiss WD, Kessler J, Slansky I, Mielke R, Szelies B, Herholz K: Activation PET
as an instrument to determine therapeutic efficacy in Alzheimer’s
disease. Ann NY Acad Sci 1993, 695:327–331.
133. Klinkhammer P, Szelies B, Heiss WD: Effect of phosphatidylserine on
cerebral glucose metabolism in Alzheimer’s disease. Dementia 1990,
1:197–201.
134. Heiss WD, Kessler J, Mielke R, Szelies B, Herholz K: Long-term effects of
phosphatidylserine, pyritinol, and cognitive training in Alzheimer’s
disease. A neuropsychological, EEG, and PET investigation. Dementia
1994, 5:88–98.
135. Brookes MJ, Wood JR, Stevenson CM, Zumer JM, White TP, Liddle PF, Morris PG:
Changes in brain network activity during working memory tasks: a
magnetoencephalography study. Neuroimage 2011, 55:1804–1815.
136. Cabeza R, Nyberg L: Imaging cognition II: an empirical review of 275 PET
and fMRI studies. J Cogn Neurosci 2000, 12:1–47.
doi:10.1186/1745-6215-14-404
Cite this article as: Scholey et al.: A randomized controlled trial
investigating the neurocognitive effects of Lacprodan® PL-20, a
phospholipid-rich milk protein concentrate, in elderly participants with
age-associated memory impairment: the Phospholipid Intervention for
Cognitive Ageing Reversal (PLICAR): study protocol for a randomized
controlled trial. Trials 2013 14:404.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Scholey et al. Trials 2013, 14:404 Page 15 of 15
http://www.trialsjournal.com/content/14/1/404
